Udvalget fandt, at fordelene ved Prialt er større end risiciene til behandling af svære kroniske smerter hos patienter med behov for intratekal smertestillende behandling.
They decided that Prialt’ s benefits are greater than its risks for the treatment of severe, chronic pain in patients who require intrathecal analgesia.